GT200300169A - Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amidadelacidoquinoxalina-2-carboxilico - Google Patents

Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amidadelacidoquinoxalina-2-carboxilico

Info

Publication number
GT200300169A
GT200300169A GT200300169A GT200300169A GT200300169A GT 200300169 A GT200300169 A GT 200300169A GT 200300169 A GT200300169 A GT 200300169A GT 200300169 A GT200300169 A GT 200300169A GT 200300169 A GT200300169 A GT 200300169A
Authority
GT
Guatemala
Prior art keywords
amidadelacidoquinoxalina
fluorobencil
dihidroxi
carboxilico
octil
Prior art date
Application number
GT200300169A
Other languages
English (en)
Inventor
John Charles Kath
Zheng Jane Li
Zhengong Bryan Li
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Christopher Stanley Poss
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT200300169A publication Critical patent/GT200300169A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMAS CRISTALINAS DE [4CARBAMOIL1(3FLUOROBENCIL)2,7DIHIDROXI7METILOCTIL]AMIDA DEL ACIDO QUINOXALINA2CARBOXILICO QUE ES DE UTILIDAD EN ENFERMEDADES AUTOINMUNES, ESTADOS INFLAMATORIOS AGUDOS Y CRONICOS, RECHAZO DE ORGANOS, ATEROSCLEROSIS, ENTRE OTROS MENCIONADOS EN LA SOLICITUD.
GT200300169A 2002-08-12 2003-08-06 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amidadelacidoquinoxalina-2-carboxilico GT200300169A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
GT200300169A true GT200300169A (es) 2004-05-12

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300169A GT200300169A (es) 2002-08-12 2003-08-06 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amidadelacidoquinoxalina-2-carboxilico

Country Status (22)

Country Link
US (1) US20040072834A1 (es)
EP (1) EP1539715A1 (es)
JP (1) JP2005538130A (es)
AP (1) AP2005003226A0 (es)
AR (1) AR040839A1 (es)
AU (1) AU2003250450A1 (es)
BR (1) BR0313378A (es)
CA (1) CA2494776A1 (es)
EC (1) ECSP055588A (es)
GT (1) GT200300169A (es)
IL (1) IL166548A0 (es)
IS (1) IS7674A (es)
MX (1) MXPA05001781A (es)
NO (1) NO20050540L (es)
OA (1) OA12894A (es)
PA (1) PA8580401A1 (es)
PE (1) PE20040866A1 (es)
TN (1) TNSN05035A1 (es)
TW (1) TW200407316A (es)
UY (1) UY27928A1 (es)
WO (1) WO2004014875A1 (es)
ZA (1) ZA200500768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731538B2 (ja) 2009-12-23 2015-06-10 アイアンウッド ファーマシューティカルズ インコーポレイテッド Crth2モジュレーター
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
KR100447553B1 (ko) * 1997-02-26 2004-09-08 화이자 인코포레이티드 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 mip-1 알파의 ccr1 수용체로의 결합에 대한 선택적 저해제로서의 용도
CN1177834C (zh) * 1998-02-05 2004-12-01 辉瑞产品公司 二羟基己酸衍生物

Also Published As

Publication number Publication date
NO20050540L (no) 2005-03-10
UY27928A1 (es) 2004-03-31
US20040072834A1 (en) 2004-04-15
TNSN05035A1 (fr) 2007-05-14
AR040839A1 (es) 2005-04-20
BR0313378A (pt) 2005-07-12
ECSP055588A (es) 2005-04-18
MXPA05001781A (es) 2005-04-25
EP1539715A1 (en) 2005-06-15
OA12894A (en) 2006-10-13
PE20040866A1 (es) 2004-11-26
IL166548A0 (en) 2006-01-15
CA2494776A1 (en) 2004-02-19
ZA200500768B (en) 2006-07-26
WO2004014875A1 (en) 2004-02-19
AP2005003226A0 (en) 2005-03-31
TW200407316A (en) 2004-05-16
IS7674A (is) 2005-01-27
AU2003250450A1 (en) 2004-02-25
PA8580401A1 (es) 2004-02-16
JP2005538130A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
BR0308385A (pt) Cristais de ácido (met) acrìlico e processo para produzir e purificar ácido (met) acrìlico aquoso
BR0115892A (pt) Novas formas de cristal de atorvastatina hemicálcica e processos para sua preparação, bem como novos processos para preparar outras formas
CR8640A (es) Proceso para producir un compuesto de 5-hidroxi-4-tiometilpirazol
PE20230156A1 (es) Sal de acido clorhidrico de (r)-4-(3-((s)-1-(4-amino-3-metil-1h pirazolo[3,4-d]pirimidin-1-il)etil)-5-cloro-2-etoxi-6-fluorofenil)pirrolidin-2-ona
HN1998000172A (es) Compuestos terapeuticamente activos basados en el reemplazo bioisostero del catecol por el indazol en inhibidores de pde4.
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
CR7876A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
EA200200819A1 (ru) Кристаллическая форма ii линезолида
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
ATE353903T1 (de) Kristalline cefdinirsalze
AR099594A2 (es) Proceso para preparar bisulfato de atazanavir y otras formas
GT200300169A (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amidadelacidoquinoxalina-2-carboxilico
GT200400195A (es) Nuevo proceso para reducir el nivel de impurezas en una muestra de mesotriona
DE50309655D1 (de) Carbaminsäureester mit anticholinerger wirksamkeit
SV2004001457A (es) "sales estables del acido o-acetilsaliciclico con aminoacidos basicos ii" lea 35839-sv
NO20030182L (no) Dermalt påföringssystem for aminolevulinsyre
PT1289930E (pt) Processo para produzir acido 5-aminosalicilico
EA200400417A1 (ru) Новые безводные кристаллические формы габапентина
IT1318467B1 (it) Processo per la sintesi di cefoperazone sodico ad elevatacristallinita'.
ES2183860T3 (es) Procedimiento para producir n-terc butil-2-pirazincarboxamida y n-ter-butil-2-piperazincarboxamida.
BRPI0416497A (pt) processo para a produção de cristais poli-hidroxialcanoato
BR0317029A (pt) Processo para a preparação de compostos peptìdicos bicìclicos
HN2002000283A (es) Nuevas formas cristalinas anhidras de la gabapentina
BR0302902A (pt) Processo para a preparação de ácido 1- (mercaptometil) - ciclopropanoacético
TWD221451S (zh) 錶帶